Earthquake Brace + Bolt Grants Now Available to More Eligible California Homeowners
SACRAMENTO, CA, February 12, 2025 (EZ Newswire) -- The 2025 Earthquake Brace + Bolt grant application window is open, according to an announcement today by the California Residential Mitigation Program (CRMP). The California Residential Mitigation Program (CRMP) announces the opening of their Earthquake Brace + Bolt grant application window for 2025. California homeowners are now eligible to apply for Earthquake Brace + Bolt ( EBB) seismic retrofit grants, to help make their home less vulnerable to earthquake damage. This year, 303 new ZIP Codes have been added, making the total number of eligible ZIP Codes 1,118. Opening January 15, 2025, and continuing through, March 26, 2025, eligible homeowners can apply for up to $3,000 in seismic retrofit grants at EarthquakeBraceBolt.com.
More than $20 million in grant funding will be available to help offset the cost of seismic retrofits that bolt older houses to their foundations and brace the crawl space walls, when present, making them less vulnerable to earthquake damage. Since the 2013 EBB program launch, more than 28,500 California homeowners have received grant assistance for strengthening their homes against earthquake damage. The EBB grant program is administered by the California Residential Mitigation Program ( CRMP), a Joint Powers Authority between the California Earthquake Authority ( CEA) and the California Governor's Office of Emergency Services ( Cal OES).
'Strengthening homes through the Earthquake Brace + Bolt program not only reduces the risk of costly damages but also gives homeowners peace of mind knowing their properties are better prepared to withstand seismic events,' said Janiele Maffei, Chief Mitigation Officer, California Earthquake Authority. 'By striving for more applications this year, we are working to make a significant impact in protecting California homes and families from the devastating effects of earthquakes.'
Income-eligible homeowners may also qualify for supplemental grants. Up to $7,000 in additional grant funds are available for households with an annual income at or below $89,040, which may provide up to 100% of the funds needed to cover a seismic retrofit. Grants are contingent upon meeting eligibility requirements and available funds.
'Earthquake retrofits are a cornerstone of creating a safer and more resilient California. By securing older homes with proven seismic strengthening measures, we not only protect families and their investments but also reduce the potential strain on communities during a major earthquake,' said Tom Welsh, Chief Executive Officer of the California Earthquake Authority. 'Every home retrofit brings us closer to a more resilient California.'
Beginning January 15 through March 26, 2025, eligible homeowners can apply for a retrofit grant at EarthquakeBraceBolt.com, where they can also find detailed program information, select a trained California-licensed general contractor and view the full list of ZIP Codes and program areas. New EBB program ZIP Codes include areas in and around Los Angeles County, Riverside and San Diego.
About Earthquake Brace + Bolt (EBB)
Established by the California Residential Mitigation Program, EBB offers up to $3,000 to help California homeowners retrofit their house to reduce potential damage from earthquakes. A residential seismic retrofit makes a house more resistant to earthquake activity, such as ground shaking and soil failure, by bolting the house to its foundation and adding bracing around the perimeter of the crawl space. For more information, including an online media kit, please visit http://www.earthquakebracebolt.com. About the California Residential Mitigation Program (CRMP)
CRMP was established in 2011 to help Californians strengthen their homes against damage from earthquakes. CRMP is a joint powers authority created by the California Earthquake Authority (CEA) and the California Governor's Office of Emergency Services (Cal OES). For more information, please visit: .
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
6 hours ago
- Business Wire
Crossbow Therapeutics Nominates its Second Development Candidate, CBX-663, a Broadly Acting Therapeutic for a Wide Range of Solid and Hematologic Malignancies
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Crossbow Therapeutics, Inc., a biotechnology company developing T-Bolt™ therapies, a novel class of T-cell receptor (TCR)-mimetic antibody therapeutics, today announced the nomination of its second development candidate, CBX-663, for the treatment of a broad range of solid tumor and hematologic malignancies. The next-generation T-cell engager targets telomerase reverse transcriptase (TERT), a protein that drives tumor growth and is expressed in up to 95% of cancers. 1,2 CBX-663, a bispecific antibody, binds to TERT-derived peptide human leukocyte antigen (pHLA) complexes on the surface of tumor cells and activates T-cells through a CD3-binding arm. The molecule includes two binding domains for TERT, which increase its ability to engage tumor cells and boost immune activation. 'CBX-663 illustrates how Crossbow's TCR-mimetic platform can unlock new opportunities for antibody-based cancer therapies,' said Briggs Morrison, MD, Chief Executive Officer of Crossbow. 'With strong preclinical performance selectively targeting a pHLA expressed across a broad range of cancers, CBX-663 has the potential to offer a meaningful new treatment option for patients with limited therapeutic options.' In preclinical studies, CBX-663 drove potent, antigen-specific tumor killing across multiple TERT-positive cancer models, with minimal activity against TERT-negative or HLA-mismatched cells. The candidate also demonstrated a favorable safety profile and pharmacokinetics comparable to conventional antibody therapies. Crossbow presented data summarizing the initial characterization of CBX-663 at the 2025 Annual Meeting of the American Association for Cancer Research (AACR). Although TERT resides inside the cell, HLA molecules can present fragments of the protein, known as peptides, on the tumor surface. CBX-663 recognizes one of those peptides, the HLA-A*02:01-restricted TERT540 peptide, and redirects T-cells to attack tumor cells. CBX-663 demonstrated broad cytotoxic activity in vitro in both solid and hematologic cancer cell lines, as well as in primary patient samples ex vivo. In vivo studies further confirmed its anti-tumor efficacy and tolerability. 'CBX-663 reflects the depth of antibody discovery and protein engineering that underpins our T-Bolt™ platform and our ability to generate highly selective, potent molecules against difficult cancer targets,' said Dmitri Wiederschain, PhD, Chief Scientific Officer of Crossbow. 'Its performance in preclinical models reinforces the promise of TCR-mimetic therapeutics, and we're excited to continue advancing this program.' Crossbow discovered and developed CBX-663 through its proprietary T-Bolt™ platform, which uses optimized antibody libraries and precision screening to find high-affinity, specific binders to intracellular tumor antigens displayed as pHLA complexes. The nomination of CBX-663 underscores the platform's potential to deliver a scalable pipeline of T-cell engagers for difficult-to-treat cancers. About Crossbow Therapeutics, Inc. Crossbow Therapeutics, Inc., is a biotechnology company determined to improve the lives of people with cancer by unlocking the therapeutic potential of T-cell receptor (TCR)-mimetic antibodies. The company's T-Bolt™ therapies are next-generation, easily assembled immunotherapies directed with high precision at previously unreachable cancer cell targets. Crossbow's efficient and selective approach is designed to target the entire universe of cancer proteins, dramatically expanding the potential of antibody therapy to address many types of cancer. For more information about Crossbow Therapeutics, visit
CNBC
21 hours ago
- CNBC
Estonia's tech elite are getting behind a European challenger to Robinhood
Some of the biggest names of Estonia's tech scene are backing Lightyear, a startup looking to become Europe's answer to commission-free trading pioneer Robinhood. Based in London, Lightyear develops an app that lets users invest in a range of over 5,000 stocks, exchange-traded funds and money market funds. It was founded by two former Wise employees, Martin Sokk and Mihkel Aamer, in 2021. The company is set to announce later on Thursday that it has raised $23 million in a new round of funding led by NordicNinja, a Japanese-backed venture capital fund based in Europe. Estonian tech entrepreneur Markus Villig, who co-founded ride-hailing unicorn Bolt has also invested. Lightyear CEO Sokk told CNBC that the firm didn't necessarily need to raise more cash for the business but chose to do so because of the caliber of investors involved. "People like Markus have been building massive companies in many, many markets, and this is something that's really exciting for us because it's so hard to go into all the markets and understand their local dynamics and what people need," he said. Lightyear currently operates in 25 countries. However, with help from angel investors like Bolt's Villig, the firm will be able to launch in another five markets "pretty quickly," Sokk said. Villig told CNBC that it can be "challenging to scale a business across multiple countries in a heavily regulated sector," adding that Europe's less developed retail investing market provides ample opportunities for disruption. Other Estonian angel investors who have previously backed Lightyear also participated in the funding round, including Wise co-founder Taavet Hinrikus, former Chief Technology Officer Ott Kaukver and Skype founding engineer Jaan Tallinn. Estonia is widely considered a prominent tech hub in Europe. The country is home to the highest number of unicorns per capita in Europe, according to the Estonian Investment Agency. Meanwhile, Estonia's e-residency scheme has also enabled foreigners to become digital residents and launch their companies in the country. The new round values five-year-old Lightyear at between $200 million and $300 million, significantly higher than its valuation in 2022 when it raised $25 million, according to two people familiar with the matter who preferred to remain anonymous as the information has not been made public. Alongside the additional funding, Lightyear is also launching new artificial intelligence features. AI has been a hot area of investment for startups following the explosive popularity of generative AI services like OpenAI's ChatGPT. One of the features, called "Why Did It Move," allows users to select a point in time on a stock chart and see what happened that day to cause a jump or fall in a company's share price. The firm is also using AI to provide "bull" and "bear" theses on stocks as well as short updates on assets in their own portfolios. "In the end, you're going to have two models" when it comes to investing, according to Sokk: "Self-driving money," where you ask an AI to achieve certain investment goals, and a "manual gearbox" approach of figuring out different strategies and approaches on your own. Still, the market for online investment products is heavily competitive. Lightyear faces some hefty competition from both incumbent brokerage services as well as more modern tech players such as Robinhood, Revolut and Trade Republic. However, Sokk insists Lightyear is building a differentiated enough product to stand out from the crowd. While competitors like Robinhood profit from offering risky products like crypto and margin trading, Lightyear is focused on serving long-term investors, he told CNBC. To that end, Sokk said Lightyear is planning on rolling out a crypto product of its own in two months' time — one that's "more focused on a long-term view."
Fast Company
3 days ago
- Fast Company
Bolt CEO Ryan Breslow was a progressive workplace innovator. Now he's axing it all
The founder of financial technology startup Bolt is back at the helm of the company—and he's been busy. Ryan Breslow originally made a name for himself by implementing progressive HR policies such as unlimited paid time off (PTO) and a four-day workweek. However, in 2022 Breslow left Bolt surrounded by a flurry of controversy, including a plan to loan employees money to buy stock options. Since returning, he's been dismantling all the policies that put him on the map as a young CEO, writing that his PTO stance 'sounds progressive, but it's totally broken.' In this exclusive interview with Fast Company, the 31-year-old entrepreneur explains how the changes fit into his culture overhaul at Bolt. Paid subscribers will learn: What he discovered about unlimited PTO that led him to change the policy The mistaken assumption employees made about the four-day workweek Where HR was 'misaligned' with Breslow's business goals and why people ops isn't Why Breslow feels 'better than ever' about the workplace culture he's creating This interview has been edited and condensed for clarity. Let's start with unlimited PTO. You said the bad employees take too much and the good ones don't take enough. How did you arrive at that conclusion? The super-early-rate deadline for Fast Company's Most Innovative Companies Awards is this Friday, July 25, at 11:59 p.m. PT. Apply today.
